leadf
logo-loader
viewTHC Global Group Ltd

THC Global welcomes interim TGA decision to down schedule CBD medicines to allow pharmacy access without prescription

The company's Southport facility is capable of manufacturing these medicines at significant scale to support Australian demand following the interim decision.

THC Global Group Ltd - THC Global Group welcomes TGA’s interim decision to down schedule CBD medicines to allow access at pharmacies without prescription
The diversified global cannabis company is exceptionally well-positioned for an expanding market in CBD medicines

THC Global Group Limited (ASX:THC) welcomes the TGA Interim Decision to down schedule cannabidiol (CBD) medicines to a new Schedule 3 (S3) entry, which allows access at pharmacies without prescription.

The diversified global cannabis company is exceptionally well-positioned for an expanding market in CBD medicines.

THC Global’s Southport facility is capable of manufacturing these medicines at significant scale to support Australian demand following the implementation of the interim decision.

Well-placed to enter the market

THC Global’s chief executive officer Jarrod White said: “We’re pleased to see the TGA take this first step in reducing barriers for patients to access pharmaceutical-grade CBD medicines through the down scheduling of CBD medicines to Schedule 3.

“In our submissions to the TGA on this issue, we have highlighted the need to ensure patient safety and responsible access.

“With the Southport Facility, we are well placed to enter this market as a high volume high-quality pharma GMP manufacturer, ensuring accessibility and affordability of these medicines to patients in need without sacrificing quality.”

THC submission

THC Global’s submission to the TGA has now been made public following the interim decision.

This submission recognised the priority of consumer safety in any down scheduling decision, and supported the increased availability of naturally sourced CBD medicines, noting its well-documented safety profile.

The company further opined on the presence of minor cannabinoids in the medicines and appropriate package warnings, leveraging its extensive body of cannabis medicine research and knowledge.

THC Global’s Southport Facility is one of the world's largest pharmaceutical GMP cannabis manufacturing facilities.

It also owns and operates Crystal Mountain, a fast-growing hydroponics equipment and supplies wholesaler and retailer servicing the rapidly expanding cannabis sector in North America and Europe.

Quick facts: THC Global Group Ltd

Price: 0.25 AUD

ASX:THC
Market: ASX
Market Cap: $43.99 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of THC Global Group Ltd named herein, including the promotion by the Company of THC Global Group Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Full interview: THC Global Group granted GMP Licence for Southport cannabis...

THC Global Group Limited (ASX:THC) chief executive officer Ken Charteris updates Proactive on being granted a licence to manufacture therapeutic goods for the company’s Southport Facility, known as a GMP Licence, by the Australian Therapeutic Goods Administration (TGA). This milestone...

on 29/1/20

2 min read